{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:05:16Z","timestamp":1779444316655,"version":"3.53.1"},"reference-count":61,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Compound repurposing is an efficient method to save both time and costs by redirecting previously synthesized small molecules towards new biological targets. In this research, we employ computational methodologies to investigate and assess target engagement of small molecules as tyrosine kinase inhibitors (TKIs). Therefore, compounds TKI.2a, TKI.2b, TKI.6, TKI.16, TKI.19, and TKI.21b identified from our earlier research, undergo assessments of molecular similarity, docking studies, and pharmacophore modeling along with those discovered through database searches. Compounds TKI.2a, TKI.2b, TKI.6, and TKI.19 appear to exhibit multi-target tyrosine kinase inhibitory activities against VEGFR-2 (Vascular Endothelial Growth Factor Receptor), RET (proto-oncogene tyrosine\u2013protein kinase receptor), PDGFR\u03b1 (Platelet-Derived Growth Factor Receptor alpha), EGFR (Epidermal Growth Factor Receptor), and HER2 (Human Epidermal Receptor) receptors. Pharmacophore models were applied for ligand-based virtual screening using defined parameters to discover candidate compounds that exhibit drug-likeness with FDA (Food and Drug Administration)-approved tyrosine kinase inhibitors. Molecular docking studies identified lead compounds for each biological target based on their overall affinity values and established interactions. Compound ChEMBL2170947 was found to be the most promising candidate for the VEGFR-2 receptor, ChEMBL5019511 for PDGFR\u03b1, ChEMBL2216869 for EGFR, and ChEMBL3355044 for HER2.<\/jats:p>","DOI":"10.3390\/molecules31101689","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:56:27Z","timestamp":1779094587000},"page":"1689","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Silico Studies of Potent Tyrosine Kinase Inhibitors: Molecular Docking and Pharmacophore Modeling Approaches"],"prefix":"10.3390","volume":"31","author":[{"given":"Evangelos","family":"Mavridis","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-5653","authenticated-orcid":false,"given":"Eleni","family":"Pontiki","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-350X","authenticated-orcid":false,"given":"Dimitra","family":"Hadjipavlou-Litina","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1021\/ar50020a002","article-title":"Quantitative Approach to Biochemical Structure-Activity Relationships","volume":"2","author":"Hansch","year":"1969","journal-title":"Acc. Chem. Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Maltarollo, V.G. (2024). Computer-Aided and Machine Learning-Driven Drug Design: From Theory to Applications, Springer Nature. Computer-Aided Drug Discovery and Design.","DOI":"10.1007\/978-3-031-76718-0"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/jm020155c","article-title":"Do Structurally Similar Molecules Have Similar Biological Activity?","volume":"45","author":"Martin","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbapap.2009.10.017","article-title":"Defining the Conserved Internal Architecture of a Protein Kinase","volume":"1804","author":"Kornev","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA)-Proteins Proteom."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wheeler, D.L., and Yarden, Y. (2015). Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease, Springer.","DOI":"10.1007\/978-1-4939-2053-2"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mavridis, E., and Hadjipavlou-Litina, D. (2025). Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262010207"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bioorg.2018.09.001","article-title":"Identification of New Pyrrolo[2,3-d]Pyrimidines as Potent VEGFR-2 Tyrosine Kinase Inhibitors: Design, Synthesis, Biological Evaluation and Molecular Modeling","volume":"81","author":"Adel","year":"2018","journal-title":"Bioorganic Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102944","DOI":"10.1016\/j.bioorg.2019.102944","article-title":"Design, Synthesis and Anticancer Evaluation of Thieno[2,3-d]Pyrimidine Derivatives as Dual EGFR\/HER2 Inhibitors and Apoptosis Inducers","volume":"88","author":"Elmetwally","year":"2019","journal-title":"Bioorganic Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1700240","DOI":"10.1002\/ardp.201700240","article-title":"Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors","volume":"350","author":"Ayyad","year":"2017","journal-title":"Arch. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115328","DOI":"10.1016\/j.bmc.2020.115328","article-title":"VEGFR-2 Inhibiting Effect and Molecular Modeling of Newly Synthesized Coumarin Derivatives as Anti-Breast Cancer Agents","volume":"28","author":"Ahmed","year":"2020","journal-title":"Bioorganic Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103798","DOI":"10.1016\/j.bioorg.2020.103798","article-title":"2-Anilinopyrimidine Derivatives: Design, Synthesis, in Vitro Anti-Proliferative Activity, EGFR and ARO Inhibitory Activity, Cell Cycle Analysis and Molecular Docking Study","volume":"99","author":"AboulWafa","year":"2020","journal-title":"Bioorganic Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"W612","DOI":"10.1093\/nar\/gkv352","article-title":"ChEMBL Web Services: Streamlining Access to Drug Discovery Data and Utilities","volume":"43","author":"Davies","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","article-title":"The ChEMBL Database in 2023: A Drug Discovery Platform Spanning Multiple Bioactivity Data Types and Time Periods","volume":"52","author":"Zdrazil","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_14","unstructured":"(2025, December 13). ChEMBL Database, Available online: https:\/\/www.ebi.ac.uk\/chembl\/."},{"key":"ref_15","unstructured":"(2025, September 26). RDKit Blog Thresholds for \u201cRandom\u201d in Fingerprints the RDKit Supports. Available online: https:\/\/greglandrum.github.io\/rdkit-blog\/posts\/2021-05-18-fingerprint-thresholds1.html."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"012015","DOI":"10.1088\/1742-6596\/892\/1\/012015","article-title":"Similarity Measure for Molecular Structure: A Brief Review","volume":"892","author":"Bero","year":"2017","journal-title":"J. Phys. Conf. Ser."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107723","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2025 Update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez, D., and Caballero, J. (2018). Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?. Molecules, 23.","DOI":"10.3390\/molecules23051038"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular Conformations, Interactions, and Properties Associated with Drug Efficiency and Clinical Performance among VEGFR TK Inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural Basis of Acquired Resistance to Selpercatinib and Pralsetinib Mediated by Non-Gatekeeper RET Mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejmech.2016.01.039","article-title":"The Discovery of 2-Substituted Phenol Quinazolines as Potent RET Kinase Inhibitors with Improved KDR Selectivity","volume":"112","author":"Newton","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Keretsu, S., Ghosh, S., and Cho, S.J. (2020). Molecular Modeling Study of C-KIT\/PDGFR\u03b1 Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218232"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"129084","DOI":"10.1016\/j.bmcl.2022.129084","article-title":"Discovery of Mobocertinib, a Potent, Oral Inhibitor of EGFR Exon 20 Insertion Mutations in Non\u2013Small Cell Lung Cancer","volume":"80","author":"Huang","year":"2023","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"118411","DOI":"10.1016\/j.ejmech.2025.118411","article-title":"Pharmacophore-Guided Review of EGFR-Targeted Anticancer Drugs with Gefitinib as a Reference","volume":"303","author":"Meenu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"28608","DOI":"10.1039\/D4RA04165H","article-title":"Design and Evaluation of Sulfadiazine Derivatives as Potent Dual Inhibitors of EGFRWT and EGFRT790M: Integrating Biological, Molecular Docking, and ADMET Analysis","volume":"14","author":"Ezelarab","year":"2024","journal-title":"RSC Adv."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Khan, M.N., Farooq, U., Khushal, A., Wani, T.A., Zargar, S., and Khan, S. (2025). Unraveling Potential EGFR Kinase Inhibitors: Computational Screening, Molecular Dynamics Insights, and MMPBSA Analysis for Targeted Cancer Therapy Development. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0321500"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s43018-022-00412-y","article-title":"Discovery of Potent and Selective HER2 Inhibitors with Efficacy against HER2 Exon 20 Insertion-Driven Tumors, Which Preserve Wild-Type EGFR Signaling","volume":"3","author":"Wilding","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18756","DOI":"10.1074\/jbc.M110.206193","article-title":"Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein","volume":"286","author":"Aertgeerts","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bmcl.2015.02.002","article-title":"Identification and Optimization of Pyridazinones as Potent and Selective C-Met Kinase Inhibitors","volume":"25","author":"Dorsch","year":"2015","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105328","DOI":"10.1016\/j.jbc.2023.105328","article-title":"Biophysical and Structural Characterization of the Impacts of MET Phosphorylation on Tepotinib Binding","volume":"299","author":"Schwarz","year":"2023","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"18872","DOI":"10.1021\/acsomega.0c02038","article-title":"Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-Thiadiazin-3-Yl)Indolin-2-One Derivatives as Angiogenesis Inhibitors","volume":"5","author":"Mohamady","year":"2020","journal-title":"ACS Omega"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Giordano, D., Biancaniello, C., Argenio, M.A., and Facchiano, A. (2022). Drug Design by Pharmacophore and Virtual Screening Approach. Pharmaceuticals, 15.","DOI":"10.3390\/ph15050646"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105019","DOI":"10.1016\/j.bioorg.2021.105019","article-title":"Discovery of Potent Thieno[2,3-d]Pyrimidine VEGFR-2 Inhibitors: Design, Synthesis and Enzyme Inhibitory Evaluation Supported by Molecular Dynamics Simulations","volume":"113","author":"Elrazaz","year":"2021","journal-title":"Bioorganic Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13321-015-0109-z","article-title":"ChemDes: An Integrated Web-Based Platform for Molecular Descriptor and Fingerprint Computation","volume":"7","author":"Dong","year":"2015","journal-title":"J. Cheminform."},{"key":"ref_35","unstructured":"(2025, September 26). FPS-Similarity-ChemDes-ChemDes-Molecular Descriptors Computing Platform. Available online: http:\/\/www.scbdd.com\/fps-similarity\/index\/."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"W486","DOI":"10.1093\/nar\/gkr320","article-title":"ChemMine Tools: An Online Service for Analyzing and Clustering Small Molecules","volume":"39","author":"Backman","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_37","unstructured":"(2025, September 26). ChemMine Tools. Available online: https:\/\/chemminetools.ucr.edu\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13321-020-0410-3","article-title":"Development of Natural Compound Molecular Fingerprint (NC-MFP) with the Dictionary of Natural Products (DNP) for Natural Product-Based Drug Development","volume":"12","author":"Seo","year":"2020","journal-title":"J. Cheminform."},{"key":"ref_39","unstructured":"RCSB Protein Data Bank (2025, July 01). RCSB PDB: Homepage. Available online: https:\/\/www.rcsb.org\/."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1021\/acs.jpcb.3c06662","article-title":"OpenMM 8: Molecular Dynamics Simulation with Machine Learning Potentials","volume":"128","author":"Eastman","year":"2024","journal-title":"J. Phys. Chem. B"},{"key":"ref_41","unstructured":"Eastman, P., Galvelis, R., Pel\u00e1ez, R.P., Abreu, C.R.A., Farr, S.E., Gallicchio, E., Gorenko, A., Henry, M.M., Hu, F., and Huang, J. (OpenMM, 2024). OpenMM, version 8.1.2."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jcc.23354","article-title":"CHARMM36 All-Atom Additive Protein Force Field: Validation Based on Comparison to NMR Data","volume":"34","author":"Huang","year":"2013","journal-title":"J. Comput. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13321-019-0358-3","article-title":"Gypsum-DL: An Open-Source Program for Preparing Small-Molecule Libraries for Structure-Based Virtual Screening","volume":"11","author":"Ropp","year":"2019","journal-title":"J. Cheminform."},{"key":"ref_45","unstructured":"Durrant, J.D. (Gypsum-DL, 2024). Gypsum-DL, version 1.2.1."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13321-021-00522-2","article-title":"GNINA 1.0: Molecular Docking with Deep Learning","volume":"13","author":"McNutt","year":"2021","journal-title":"J. Cheminform."},{"key":"ref_47","unstructured":"McNutt, A.T., Francoeur, P., Aggarwal, R., Masuda, T., Meli, R., Ragoza, M., Sunseri, J., and Koes, D.R. (GNINA, 2021). GNINA, version 1.0."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/acs.jcim.0c00411","article-title":"Three-Dimensional Convolutional Neural Networks and a Cross-Docked Data Set for Structure-Based Drug Design","volume":"60","author":"Francoeur","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_49","unstructured":"Schr\u00f6dinger, LLC (PyMOL Molecular Graphics System, 2021). PyMOL Molecular Graphics System, version 3.0.4."},{"key":"ref_50","unstructured":"(Schr\u00f6dinger Release 2025-3: Maestro, 2025). Schr\u00f6dinger Release 2025-3: Maestro, version 14.5.131."},{"key":"ref_51","unstructured":"Python Software Foundation (Python Language Reference, 2011). Python Language Reference, version 3.2.2."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_53","unstructured":"(2025, September 22). InformaticsMatters Docking-Validation\/Datasets\/DEKOIS_2.0 at Master InformaticsMatters\/Docking-Validation. Available online: https:\/\/github.com\/InformaticsMatters\/docking-validation\/tree\/master\/datasets\/DEKOIS_2.0."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters","volume":"45","author":"Wolber","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"ref_55","unstructured":"(LigandScout, 2025). LigandScout, version 4.5."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"W442","DOI":"10.1093\/nar\/gkw287","article-title":"Pharmit: Interactive Exploration of Chemical Space","volume":"44","author":"Sunseri","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_57","unstructured":"(2025, July 01). Pharmit Search Engine. Available online: https:\/\/pharmit.csb.pitt.edu\/search.html."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","article-title":"Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-Ylmethyl)-1H-[1,2,3]Triazolo[4,5-b]Pyrazin-6-Yl)-1H-Pyrazol-1-Yl)Ethanol (PF-04217903) for the Treatment of Cancer","volume":"55","author":"Cui","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.slasd.2022.07.002","article-title":"Replenishing the Malaria Drug Discovery Pipeline: Screening and Hit Evaluation of the MMV Hit Generation Library 1 (HGL1) against Asexual Blood Stage Plasmodium Falciparum, Using a Nano Luciferase Reporter Read-Out","volume":"27","author":"Dechering","year":"2022","journal-title":"SLAS Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1021\/jm300847w","article-title":"PI3K\u03b4 and PI3K\u03b3 as Targets for Autoimmune and Inflammatory Diseases","volume":"55","author":"Cushing","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/ml500482q","article-title":"Pyrrolopyridines-Quinazolines Inhibitors of PKR-Like ER Kinase","volume":"6","author":"Rosse","year":"2015","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/10\/1689\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:17:30Z","timestamp":1779441450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/10\/1689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["molecules31101689"],"URL":"https:\/\/doi.org\/10.3390\/molecules31101689","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]}}}